Free shipping on all orders over $ 500

Ursodeoxycholic acid sodium

Cat. No. M13985
Ursodeoxycholic acid sodium Structure

Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium

Size Price Availability Quantity
500mg USD 98  USD98 In stock
1g USD 175  USD175 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active.

Chemical Information
Molecular Weight 414.55
CAS Number 2898-95-5
Solubility (25°C) DMSO 90 mg/mL
Storage 2-8°C, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Xintong Zhang, et al. The influence of the gut microbiota on the bioavailability of oral drugs

[2] Aliya F Gulamhusein, et al. Primary biliary cholangitis: pathogenesis and therapeutic opportunities

[3] Huey-Ling Chen, et al. Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases

[4] Lili Ding, et al. Bile acid nuclear receptor FXR and digestive system diseases

[5] Nisanne S Ghonem, et al. Fibrates and cholestasis

Related GPCR19/TGR5 Products

SB756050 is a selective TGR5 agonist. SB756050 has the potential for type 2 diabetes treatment.

Deoxycholic acid sodium salt

Deoxycholic acid sodium salt activates the G protein-coupled bile acid receptor TGR5.


SBI-115 is a TGR5 (GPCR19) antagonist, it decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5.


INT-777 is a potent TGR5 agonist with EC50 of 0.82 μM.

BAR 502

BAR502 is a dual agonist of FXR and GPBAR1 with IC50 values of 2 μM and 0.4 μM, respectively.

Abmole Inhibitor Catalog

Keywords: Ursodeoxycholic acid sodium, Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium supplier, GPCR19/TGR5, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.